gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 7, 2001, Pages 1977-1981

  Oh, H ^a   El Amin, N ^a   Davies, T ^a   Appelbaum, P C ^a   Edlund, C ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; ESCHERICHIA COLI; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; HUMAN; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE;

AMINO ACID SUBSTITUTION; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BACTEROIDES FRAGILIS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; QUINOLINES;

EID: 0034962121     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.7.1977-1981.2001     Document Type: Article

References (32)

1. Roles of gyrA mutations in resistance of clinical isolates and in vitro mutants of Bacteroides fragilis to the new fluoroquinolone trovafloxacin
2. Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis
3. In vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin
4. Sequencing of gyrase and topoisomerase. IV. Quinolone resistance-determining region of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro
5. DNA gyrase, topoisomerase IV, and the 4-quinolones
6. DNA topoisomerase IV as a secondary quinolone target
7. Alterations in GyrA and Parc associated with fluoroquinolone resistance in Enterococcus faecalis
8. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
9. Anaerobic infections in humans: An overview
10. Involvement of an efflux system in high-level fluoroquinolone resistance of Shigella dysenteriae
11. Novel quinolone resistance mutations of the Escherichia coli DNA gyrase A protein: Enzymatic analysis of the mutant proteins
12. Escherichia coli K-12 mutants resistant to nalidixic acid: Genetic mapping and dominance studies
13. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa
14. Activity of quinolones against viridans group streptococci isolated from blood cultures of patients with haematological malignancy
15. Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis
16. Bay 12-8039, a new 8-methoxy-quinolone: Comparative in-vitro activity with nine other antimicrobial agents against anaerobic bacteria
17. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA
18. Active efflux of norfloxacin by Bacteroides fragilis
19. Semi-microtechnnique for the biochemical characterization of anaerobic bacteria
20. Ecological disturbances in intestinal microflora caused by clinafloxacin, an extended-spectrum quinolone
21. Sequence analysis of the gyrA and parC homologues of a wild-type strain of Vibrio parahaemolyticus and its fluoroquinolone-resistant mutants
22. A primer on anaerobic bacteria and anaerobic infections for the uninitiated
23. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase
24. Efflux-mediated resistance to fluoroquinolones in gram- negative bacteria
25. PCR-restriction fragment length polymorphism analysis for identification of Bacteroides spp. and characterization of nitroimidazole resistance genes
26. Antimicrobial resistance of Neisseria gonorrhoeae and high prevalence of ciprofloxacin-resistant isolates in Japan, 1993 to 1998
27. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates
28. Minimizing quinolone resistance: Are the new agents more or less likely to cause resistance?